#USA #FDA #Cambrex #High Point

Cambrex High Point Strengthens Commercial Manufacturing Capability

Cambrex, a prominent player in the contract development and manufacturing organization (CDMO) sector, recently announced a significant milestone at its facility in High Point, North Carolina. On August 25, 2026, the company revealed the successful conclusion of three Pre-Approval Inspections (PAIs) conducted by the United States Food and Drug Administration (FDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and Australia’s Therapeutic Goods Administration (TGA). This achievement further solidifies Cambrex's capabilities in the realm of commercial pharmaceutical production.

These inspections are crucial evaluations that regulatory agencies execute to assess various aspects of a facility, including quality systems, manufacturing processes, data integrity, and operational controls. With the approval secured from these agencies, the High Point site is now fully authorized to manufacture approved active pharmaceutical ingredients (APIs) not only for the U.S. market but also for Japan and Australia. This expansion of regulatory approval makes the High Point facility the latest addition to Cambrex's global network of commercial manufacturing sites.

The accomplishment of completing these inspections follows on from a substantial $38 million expansion of the High Point facility that was finalized in 2023. This upgrade resulted in the establishment of advanced analytical laboratories, laboratories for chemical development, clinical manufacturing spaces, and commercial production facilities equipped with reactors boasting capacities of up to 2,000 liters. The High Point site is specifically designed to support the production of smaller batch commercial products, including orphan drugs, precision medicines, and other specialized therapies geared towards niche patient populations.

Thomas Loewald, Chief Executive Officer of Cambrex, emphasized the significance of these recent inspections, stating, “The successful completion of these inspections underlines the strength of our quality systems and the dedication of the High Point team.” As the pharmaceutical industry increasingly pivots towards therapies tailored for specific patient demographics, the demand for smaller-scale commercial production capacities is surging. High Point's design directly addresses this market need, providing clients with an efficient and flexible pathway from drug development to long-term commercial supply.

The High Point facility enhances Cambrex’s expansive global development and manufacturing network, offering clients a seamless experience from process development right through to clinical and commercial manufacturing. This expansion not only bolsters Cambrex's infrastructural capabilities but also reinforces the company’s ability to support customer programs throughout the entire product lifecycle.

With over 45 years of industry experience, Cambrex stands as a leader in the field of contract development and manufacturing. The company specializes in the development and production of active pharmaceutical ingredients, complemented by a broad array of analytical services. With a skilled workforce of 2,000 experts serving global clientele from North America and Europe, Cambrex provides specialized technologies and expertise in drug substance manufacturing. These specialties include continuous flow processes, controlled substances, peptide synthesis, solid-state chemistry, biocatalysis, material characterization, complex synthesis, and high-potency APIs.

As the pharmaceutical landscape evolves, Cambrex High Point is well-positioned to meet growing demands and play a vital role in bringing new therapies to market efficiently, ensuring that patients receive the innovative treatments they need with timely availability.